Regístrese
Buscar en
Enfermedades Infecciosas y Microbiología Clínica
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica Pediatric case of fatal necrotizing pneumonia due to Panton-Valentine leukocidin...
Información de la revista
Vol. 37. Núm. 1.
Páginas 63 (Enero 2019)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 37. Núm. 1.
Páginas 63 (Enero 2019)
Scientific letter
DOI: 10.1016/j.eimc.2018.02.005
Acceso a texto completo
Pediatric case of fatal necrotizing pneumonia due to Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus in Spain
Caso pediátrico de neumonía necrotizante fatal debida a Staphylococcus aureus productor de Leucocidina de Panton-Valentine en España
Visitas
280
Margarita Mosqueraa,b,
Autor para correspondencia
mmosquera@fhalcorcon.es

Corresponding author.
, Laura Monteroa, Francisco J. Pérez-Lescurec, Andrés Aragónd
a Preventive Medicine Department, Alcorcon University Hospital Foundation, Madrid, Spain
b Preventive Medicine and Public Health and Medical Immunology and Microbiology Department, King Juan Carlos University, Madrid, Spain
c Paediatric Department, Alcorcón University Hospital Foundation, Madrid, Spain
d Epidemiology Unit, Regional Ministry of Health, Community of Madrid, Madrid, Spain
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Texto completo

Methicillin-resistant Staphylococcus aureus (MRSA) is a leading cause of hospital-acquired and health care-associated infection worldwide. However, over recent decades, MRSA epidemiology has changed causing infections in the healthy community.1 Production of Panton-Valentine leukocidin (PVL), a cytotoxin that causes leukocyte destruction and tissue necrosis in these strains is considered a virulence factor. PVL genes are consistently associated with skin and soft-tissue infections2 in immunocompetent young patients although its role in invasive disease with poor prognosis is controversial.2–4 PVL toxin can be produced by both methicillin-susceptible S. aureus (MSSA) and MRSA strains and is associated with more severe infections, regardless of methicillin resistance.3 We report the case of a 12-years old, previously healthy girl born in Venezuela, triplet from a multiple gestation with two healthy sisters and family with low socioeconomic status. She had been living in Spain for the last seven months.

The patient started with progressive worsening flu-like symptoms, high fever and cough that progressed to haemoptysis in less than 24h presenting sudden death at her home while sleeping. The autopsy established multiple organ failure after bilateral abscessed pneumonia as a cause of death, with pleurisy fibrinopurulent and bilateral adrenal hemorrhage. Blood culture, pleural fluid, cerebrospinal fluid and tissue biopsy of lungs, spleen, adrenal and pharynx were collected and sent for microbiology cultures postmortem. MRSA, also resistant to clindamycin and erythromycin, was isolated in all samples. Typing of MRSA strains was performed by phage typing and detection of PVL genes by the polymerase chain reaction technique, with the following results: fagogroup III, phage types 84 and 85, with positive PVL and mecA genes. All strains isolated showed the same pulsed-field gel electrophoretic pattern.

The risk of infection and/or colonization of the adolescent based on any current skin infections or previous healthcare contact during the previous year of the patient or her relatives were evaluated with no findings.

The status of colonization of the patient's cohabitants was studied. Screening was performed on 4 family members (mother, 2 sisters and brother) and 2 roommates originating from Ecuador. Screening included a swab of any suspicious lesion, nose, throat, perineum and inguinal area. Contacts underwent a five-day decolonization treatment including an intranasal application of mupirocin ointment three times a day, gargle with an antiseptic solution and chlorhexidine 4% as liquid soap in place of body wash and shampoo.5 A sister of the deceased was found to be carrying MRSA in mucous, which was negative for the PVL gene. New decolonization-treatment was not indicated as the efficacy of decolonization in patients with community-associated MRSA has not been established by any data and the possibility of relapsing following decolonization treatment has been described.6 Additional measures to reduce the risk of cross-infection within household as regular vacuuming, dusting, cleaning hard surfaces and soft furnishings with soap and water and/or 1:10 diluted bleach were provided.

The increase of morbidity and mortality associated with PVL-SA is of concern in Spain. A significant increase in the incidence of community-associated MRSA from 0.7% in 2004 to 8.8% in 2012 has been reported. The emergence of PVL-MRSA is more recent in Spain (mainly from South America immigrants) than in the rest of Europe.1 One of the most important life-threatening conditions due to PVL-Staphylococcus aureus (PVL-SA) reported is hemorrhagic necrotizing pneumonia with a high mortality rate.4 Characteristic patterns include a rapidly extensive pneumonia occurring in young patients after an influenza-like illness.7,8

A PVL-SA infection should be suspected if a patient with influenza-like illness associate haemoptysis, hypotension, high fever, leukopenia and/or multilobal lung infiltrates, which can be cavitated,9 especially in epidemic flu period. The rareness in our country of severe cases of PVL-SA infection, especially when we found a MSSA, needs a greater awareness,10 establishing an action guide with preventive measures and systematic notification to the epidemiological surveillance network as exist in other countries.5

Conflict of interest

No honorarium, grant, or other form of payment was given to anyone to produce the manuscript. No conflict of interest.

References
[1]
A. Vindel, P. Trincado, O. Cuevas, C. Ballesteros, E. Bouza, E. Cercenado.
Molecular epidemiology of community-associated methicillin-resistant Staphylococcus aureus in Spain: 2004–12.
J Antimicrob Chemother, 69 (2014), pp. 2913-2919
[2]
L.J. Shallcross, E. Fragaszy, A.M. Johnson, A.C. Hayward.
The role of the Panton-Valentine leucocidin toxin in staphylococcal disease: a systematic review and meta-analysis.
[3]
M. Gijón, M. Bellusci, B. Petraitiene, A. Noguera-Julián, V. Zilinskaite, P. Sanchez-Moreno, et al.
Factors associated with severity in invasive community-acquired Staphylococcus aureus infections in children: a prospective European multicentre study.
Clin Microbiol Infect, 643 (2016),
e1–643.e6
[4]
Y. Gillet, B. Issartel, P. Vanhems, J.C. Fournet, G. Lina, M. Bes, et al.
Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients.
[5]
Guidance on the diagnosis and management of PVL-associated Staphylococcus aureus infections (PVL-SA) in England.
2nd ed., Steering Group of Health Care Associated Infection, (2008, November),
[6]
A.E. Simor.
Staphylococcal decolonisation: an effective strategy for prevention of infection?.
Lancet Infect Dis, 11 (2011), pp. 952-962
[7]
L. O’Brian, N. Donegan, A. Flaniken, D. Rogers, R. Myers, J. Razeq, et al.
Severe coinfection with seasonal influenza A (H3N2) virus and Staphylococcus aureus.
MMWR, 61 (2012), pp. 289-291
[8]
J. Rájová, R. Pantucek, P. Petras, I. Varbanovova, I. Maslanova, J. Benes.
Necrotizing pneumonia due to clonally diverse Staphylococcus aureus strains producing Panton-Valentine leukocidin: the Czech experience.
Epidemiol Infect, 144 (2016), pp. 507-515
[9]
I. Obando, E.S. Valderrabanos, J.A. Millan, O.W. Neth.
Necrotising pneumonia due to influenza A (H1N1) and community-acquired methicillin-resistant Staphylococcus aureus clone USA300: successful management of the first documented paediatric case.
Arch Dis Child, 95 (2010), pp. 305-306
[10]
A.L. Frank.
Staphylococcus aureus: a moving target.
J Pediatr, 151 (2007), pp. 561-563
Copyright © 2018. Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.